Dear colleagues! after exciting ASH 2021 and EHA 2022 annual congresses and fundamental updates in the field of DLBCL, the idea was born to organize a preceptorship-meeting at University Hospital Würzburg (UKW). German and international colleagues discussed the changed DLBCL landscape and arising implications. Our main scientific objectives were:
Discussion of the updated DLBCL treatment landscape
Exchange of “hands on experience” regarding novel therapies under peers
Increase of awareness of novel treatment-sequencing modalities within the community.
We are happy to let you re-live the meeting via our on-demand videos Best regards,
Johannes Düll, Senior physician Universitätsklinik Würzburg
Welcome and introduction Dr. med. Johannes Düll
DLBCL: Classification and Molecular Aspects Prof. Dr. med. Andreas Rosenwald
DLBCL treatment landscape: where we come from Professor Gilles Salles
DLBCL Imaging: from CT to FDG PET Prof. Dr. med. Andreas Buck
First line DLBCL – State of the art – from EPOCH-R toPolarix Prof. Dr. med. Peter Borchmann
CD19 a target to cure? Dr. med. Johannes Düll
Second line DLBCL – Many options one direction? – From R-GemOx to CAR T Prof. Dr. med. Max Topp
Third line and beyond – from SOC to clinical trials Prof. Dr. med. Georg Lenz
Sequencing therapies – case studies and discussion Prof. Dr. med. Björn Chapuy Anna Ruckdeschel